← All trials
NCT00302341
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2006
- Primary completion
- Dec 1, 2008
- Completion date
- Dec 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Immtech Pharmaceuticals, IncLead sponsor
- University of California, San FranciscoOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- University of ChicagoOverall official - principal investigator
- Henry Ford Health SystemOverall official - principal investigator
- Medical University of South CarolinaOverall official - principal investigator
- New York UniversityOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.